Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
Ulcerative Colitis
Prospective, Longitudinal Multicentric Survey in the Therapeutic Care of Mild to Moderate Ulcerative Colitis
The primary objective of this study is to confirm the long-term efficacy (remission and maintenance in remission) of current validated treatments. Each patient will be followed during 3 years in this non-interventional trial.
- Trial name
- OPTIMUM (NCT01387698)
- Where
- 158 sites in France
- Volunteers
- 812 people
- Sponsor
- Ferring Pharmaceuticals
Colitis, Ulcerative
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.
- Trial name
- EFFECT-UC (NCT06294925)
- Testing
- Etrasimod
- Where
- 41 sites in Canada, Germany and 1 more
- Volunteers
- 360 people
- Sponsor
- Pfizer
Colitis, Ulcerative
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely…
- Trial name
- LAUREL (NCT02165215)
- Testing
- Etrolizumab
- Where
- 104 sites in United States, Brazil and 13 more
- Volunteers
- 359 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.
The purpose of this study was to demonstrate that mesalazine 4g orally per day once daily (QD) is non-inferior to the reference regimen, mesalazine 4g per day in two divided doses (BID) (2g x 2 per day), in patients with active…
- Trial name
- NCT00737789
- Testing
- Mesalazine slow-release granules, Mesalazine liquid enema
- Where
- 66 sites in Belgium, France and 2 more
- Volunteers
- 206 people
- Sponsor
- Ferring Pharmaceuticals
Crohn Disease, Ulcerative Colitis
Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease
The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in patients with ulcerative colitis and Crohn disease.
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
- Trial name
- NCT07383597
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- Efferon JSC
Ulcerative Colitis
A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT00853099
- Testing
- adalimumab
- Where
- 65 sites in Japan
- Volunteers
- 274 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
The study has been designed as a randomised, parallel-group, double-blind, 2 arm study of the comparative efficacy, safety and immunogenicity of AVT16 and Entyvio in male and female subjects with moderate to severe active…
- Trial name
- NCT06570772
- Testing
- AVT16, Vedolizumab
- Where
- 100 sites in Argentina, Bulgaria and 9 more
- Volunteers
- 301 people
- Sponsor
- Alvotech Swiss AG
Ulcerative Colitis
Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment
For both induction of remission and in maintenance of remission, different doses and treatment durations are used in practice. The aim of this study is to assess how mesalazine is used in clinical practice, at which doses and for…
- Trial name
- IMPACT (NCT02261636)
- Testing
- mesalazine
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Ferring Pharmaceuticals
Colitis, Ulcerative, Crohn's Disease
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative colitis (UC) and Crohn's disease (CD).
- Trial name
- NCT02620046
- Testing
- Vedolizumab SC
- Where
- 301 sites in United States, Argentina and 31 more
- Volunteers
- 746 people
- Sponsor
- Takeda
Ulcerative Colitis
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
The purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day delayed-release phosphatidylcholine (LT-02) versus placebo for the maintenance of remission in patients with ulcerative colitis (UC)
- Trial name
- PROTECT-2 (NCT02280629)
- Testing
- LT-02, Mesalamine
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Dr. Falk Pharma GmbH
Ulcerative Colitis, Active Moderate
Adacolumn in Refractory UC Patients Trial
The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients.
- Trial name
- ART (NCT01481142)
- Testing
- (GMA) Adsorptive Apheresis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Ulcerative Colitis
PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation limited to colonic mucosa. Its pathogenesis is not still clear, even if a multifactorial aetiology has been advocated.
- Trial name
- PROREM UC (NCT03415711)
- Testing
- VSL#3®, Mesalamine
- Where
- Italy
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- VSL Pharmaceuticals
Ulcerative Colitis, Crohn Disease
HMPL004-6599 Phase I Dose-escalating Study
To assess the safety and tolerability of single and multiple doses of HMPL004-6599 in healthy male volunteers
- Trial name
- NCT03597971
- Testing
- HMPL004-6599
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Nutrition Science Partners Limited
Ulcerative Colitis
Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis
This is a Phase 2, randomized, double-blind, multicenter, parallel, placebo controlled study. Approximately 120 eligible patients with mild-to-moderate active ulcerative colitis will be randomized to double blind treatment of…
- Trial name
- NCT01612039
- Testing
- ASP3291
- Volunteers
- 112 people
- Sponsor
- Telsar Pharma Inc.
Ulcerative Colitis (UC)
LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)
A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis
- Trial name
- NCT06749795
- Testing
- LIV001
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- Liveome Inc.
Colitis, Ulcerative
Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients
The study will investigate efficacy of STW5-II as add-on therapy on the rate to remission in patients with mild to moderate ulcerative colitis in an acute flare.
- Trial name
- NCT02246686
- Testing
- STW5-II (Iberogast N, BAY98-7410)
- Where
- 8 sites in Germany
- Volunteers
- 3 people
- Sponsor
- Bayer
Ulcerative Colitis
Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis
Confirmation of safety profile
- Trial name
- NCT01517594
- Where
- 30 sites in Czechia
- Volunteers
- 568 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan
Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Participants with UC have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon.
- Trial name
- NCT05791526
- Where
- 114 sites in Japan
- Volunteers
- 308 people
- Sponsor
- AbbVie
Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
The purpose of this study is to evaluate efficacy and safety of ZYIL1 oral capsule twice a day for 12 weeks for treatment of mild to moderate active ulcerative colitis resistant or intolerant to oral aminosalicylates.
- Trial name
- NCT06398808
- Testing
- Arm1, Arm 2
- Where
- India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Ulcerative Colitis
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.
- Trial name
- NCT00279435
- Testing
- visilizumab
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 25 people
- Sponsor
- Facet Biotech